enGene Therapeutics Inc.: PERCEPTIVE ADVISORS LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Perceptive Advisors LLC amended its Schedule 13G filing on enGene Therapeutics Inc., disclosing a change in its passive stake in the company under SEC accession 0001193125-26-463806. The filing reflects the investment firm's updated beneficial ownership position in the clinical-stage gene therapy developer. Schedule 13G amendments are typically triggered when an investor's ownership crosses certain thresholds or when previously reported holdings change materially. The update signals continued institutional interest in enGene, which trades as a small-cap biotech. Investors will watch for further 13G or 13D filings to gauge whether Perceptive's position is growing or being trimmed, and for any corresponding changes in enGene's shareholder base.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Perceptive Advisors LLC, enGene Therapeutics Inc.